A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Renaissance Technologies LLC holds 174,500 shares of BPMC stock, worth $15.8 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
174,500
Previous 110,400 58.06%
Holding current value
$15.8 Million
Previous $11.9 Million 35.6%
% of portfolio
0.03%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$84.1 - $120.5 $5.39 Million - $7.72 Million
64,100 Added 58.06%
174,500 $16.1 Million
Q2 2024

Aug 09, 2024

BUY
$85.18 - $108.78 $5.36 Million - $6.84 Million
62,900 Added 132.42%
110,400 $11.9 Million
Q1 2024

May 13, 2024

BUY
$73.17 - $99.79 $3.48 Million - $4.74 Million
47,500 New
47,500 $4.51 Million
Q4 2022

Feb 13, 2023

BUY
$41.06 - $66.48 $3.51 Million - $5.68 Million
85,400 New
85,400 $3.74 Million
Q2 2022

Aug 12, 2022

SELL
$45.23 - $70.15 $3.09 Million - $4.8 Million
-68,400 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$54.1 - $110.08 $3.7 Million - $7.53 Million
68,400 New
68,400 $4.37 Million
Q3 2021

Nov 12, 2021

SELL
$80.98 - $109.47 $12.3 Million - $16.7 Million
-152,374 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$82.78 - $101.0 $3.89 Million - $4.75 Million
-47,026 Reduced 23.58%
152,374 $13.4 Million
Q1 2021

May 13, 2021

SELL
$90.71 - $108.28 $7.48 Million - $8.93 Million
-82,500 Reduced 29.27%
199,400 $19.4 Million
Q4 2020

Feb 10, 2021

BUY
$92.08 - $124.48 $8.9 Million - $12 Million
96,700 Added 52.21%
281,900 $31.6 Million
Q3 2020

Nov 13, 2020

BUY
$66.45 - $92.7 $8.34 Million - $11.6 Million
125,500 Added 210.22%
185,200 $17.2 Million
Q2 2020

Aug 13, 2020

SELL
$57.09 - $79.27 $2.83 Million - $3.92 Million
-49,500 Reduced 45.33%
59,700 $4.66 Million
Q1 2020

May 14, 2020

BUY
$48.11 - $82.22 $5.25 Million - $8.98 Million
109,200 New
109,200 $6.39 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.